SCHEMBL6138566

SCHEMBL6138566

COC(=O)CCCCC(O)/C=C/c1ccccc1OCc1ccc(C2CCCCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.41
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
PPARA Q07869 1/20 0.37
PTGER2 P43116 2/20 0.37
PTGER1 P34995 1/20 0.37
PTGER4 P35408 1/20 0.37
PTGER3 P43115 1/20 0.37
CSF1R P07333 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
BLM P54132 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SGMS2 Q8NHU3 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3601150 0.90 FFAR4 (0.44) PTGER2PTGER1PTGER4PTGER3CSF1R
SCHEMBL3601148 0.90 FFAR4 (0.44) PTGER2PTGER1PTGER4PTGER3CSF1R
SCHEMBL6138624 0.86 PTGER4 (0.43) TP53HPGDPTGER2PTGER1PTGER4
SCHEMBL13443165 0.81 PTGFR (0.40) PPARGPTGER2PTGER1PTGER4PTGER3
SCHEMBL3591301 0.79 PTGER1 (0.37) PPARGPTGER2PTGER1PTGER4PTGER3
SCHEMBL13443265 0.78 HPGD (0.36) TP53HPGDCSF1RMEN1KMT2A
SCHEMBL13443300 0.77 KMT2A (0.42) PPARGHPGDPTGER2PTGER1PTGER4
SCHEMBL3601624 0.77 POLB (0.42) PTGER2PTGER1PTGER4PTGER3MEN1
SCHEMBL3590630 0.76 PTGER1 (0.48) PTGER2PTGER1PTGER4PTGER3MEN1
SCHEMBL3590625 0.76 PTGER1 (0.48) PTGER2PTGER1PTGER4PTGER3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674825-B2 Dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2010-03-09 US disclosed
US-7674825-B2 Dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT (DE) 2010-03-09 US disclosed
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT 2008-03-06 US disclosed
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties BAYER AKTIENGESELLSCHAFT 2008-03-06 US disclosed
EP-1216223-B1 NOVEL DICARBOXYLIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES BAYER HEALTHCARE AG (DE) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058314-A1 Novel dicarboxylic acid derivatives with pharmaceutical properties PC, GOT2, SDHA PPARG 206/4885TP53 3656/4885HPGD 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.